Inhibitex
Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent.
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed Inhibitex Information
Inhibitex was acquired by
Bristol Myers Squibb.
The acquisition happend on 2012-01-07.
Details of the transaction were not public
Acquirer
Geographic Data
Address:
City: Alpharetta
State: Georgia
Zip:
Country: United States
Financial Info
Stage:
post ipo equity
Raised Last:
$23M
Raised Total:$122M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. They are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Their pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections.
Contact Phone:
Contact Email:
Inhibitex went public on 6/4/2004 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
6/4/2004
IPO Valuation:
$119M
Ticker Symbol:
INHX
IPO Price:
$7/share
Amount Raised:
$35M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 2/2002 | Venture Round | 6 | $20M |
Alliance Technology Ventures CDP Sofinov Essex Woodlands Healthcare Partners New Enterprise Associates Pacific Horizon Ventures William Blair Alliance Technology Ventures CDP Sofinov Essex Woodlands Healthcare Partners New Enterprise Associates Pacific Horizon Ventures William Blair |
6/2000 | Series C | $15M | 10/2003 | Grant | 1 | $300k |
U.S. Food and Drug Administration U.S. Food and Drug Administration |
10/2009 | Post-IPO Equity | $23M | 1/2004 | Series E | $18.3M | 4/2002 | Series D | $45M |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
